Frequent hemodialysis improves cardiovascular surrogates and quality-of-life indicators, but its effect on survival remains unclear. We used a matched-cohort design to assess relative mortality in daily home hemodialysis and thrice-weekly in-center hemodialysis patients between 2005 and 2008. We matched 1873 home hemodialysis patients with 9365 in-center patients (i.e., 1:5 ratio) selected from the prevalent population in the US Renal Data System database. Matching variables included first date of follow-up, demographic characteristics, and measures of disease severity. The cumulative incidence of death was 19.2% and 21.7% in the home hemodialysis and in-center patients, respectively. In the intention-to-treat analysis, home hemodialysis associated with a 13% lower risk for all-cause mortality than in-center hemodialysis (hazard ratio [HR], 0.87; 95% confidence interval [95% CI], 0.78-0.97). Cause-specific mortality HRs were 0.92 (95% CI, 0.78-1.09) for cardiovascular disease, 1.13 (95% CI, 0.84-1.53) for infection, 0.63 (95% CI, 0.41-0.95) for cachexia/dialysis withdrawal, 1.06 (95% CI, 0.81-1.37) for other specified cause, and 0.59 (95% CI, 0.44-0.79) for unknown cause. Findings were similar using as-treated analyses. We did not detect statistically significant evidence of heterogeneity of treatment effects in subgroup analyses. In summary, these data suggest that relative to thrice-weekly in-center hemodialysis, daily home hemodialysis associates with modest improvements in survival. Continued surveillance should strengthen inference about causes of mortality and determine whether treatment effects are homogeneous throughout the dialysis population.
Thrice-weekly in-center hemodialysis has been the dominant renal replacement therapy in the United States for .30 years. 1 Challenges associated with it include excess fluid accumulation, dysregulated bone and mineral metabolism, vascular access infection, and anemia secondary to blood loss and hemolysis. [1] [2] [3] More frequent hemodialysis has been suggested to approximate continuous glomerular filtration; improvements in BP and phosphorus clearance have frequently been observed. [4] [5] [6] Whether such mechanisms result in lower mortality risk is unknown, as observational studies that have reported improved survival with more frequent dialysis were relatively small and/or incompletely adjusted for selection bias. [7] [8] [9] [10] [11] The popularity of home hemodialysis has recently risen in the United States. According to the ESRD Network Organizations Program, the number of home hemodialysis patients increased from 1481 at the end of 2004 to 4836 at the end of 2009. 12 Although the periodicity of daily home hemodialysis (DHHD) may be efficacious, in-home treatment requires increased attention to hygiene techniques for vascular access and equipment maintenance. In this study, we assessed the relative mortality of DHHD and matched thrice-weekly in-center patients between 2005 and 2008 . DHHD patients initiated use of the NxStage System One between 2005 and 2007. Because the NxStage System One is the only portable hemodialysis machine approved by the US Food and Drug Administration for in-home treatment, its users represent the largest subset of home hemodialysis patients. Matched in-center patients were identified from the US Renal Data System (USRDS) database; matching factors included first date of follow-up, demographic characteristics, and disease severity measures. Despite matching, the possibility of unmeasured confounding persists, as in all observational comparisons of treatments.
RESULTS

Descriptive Analyses
The study cohort included 1873 DHHD patients, of whom 1586 (84.7%) had Medicare as the primary payer during the 3 months preceding NxStage System One use initiation. Counts of new DHHD patients were 202 (10.8%), 619 (33.0%), and 1052 (56.2%) in 2005, 2006 , and 2007, respectively. Characteristics of DHHD patients, matched thrice-weekly in-center patients, and all thrice-weekly in-center patients alive on January 1, 2007, are displayed in Table 1 . Compared with the entire in-center population, DHHD patients were younger (mean age 52.2 versus 62.6 years), more likely to be wait-listed for kidney transplant (35.0% versus 14.2%), less likely to have congestive heart failure (26.9% versus 44.6%), and less likely to be black (26.5% versus 38.8%). DHHD patients also accumulated fewer hospital days (mean 2.3 versus 4.0) and had longer ESRD duration (5.5 versus 4.0 years). After matching, characteristics of DHHD and in-center patients were generally balanced (standardized differences ,7%), although an excess of dually eligible Medicare/Medicaid beneficiaries persisted in the in-center population (prevalence, 35.4% versus 23.2%). Regarding the cumulative number of factors by which DHHD patients were successfully matched with incenter patients, 34.3%, 50.3%, and 91.3% of DHHD patients were matched according to 17, at least 15, and at least 8 factors, respectively.
Survival Analyses
In intention-to-treat analysis, 360 (cumulative incidence, 19.2%) and 2033 (21.7%) deaths occurred in DHHD and matched in-center patients, respectively. Corresponding mortality rates were 110 and 127 deaths per 1000 patient-years, with mean follow-up of 1.8 and 1.7 years, respectively. Survival estimates are displayed in Figure 1A . Survival percentages in DHHD versus in-center patients were 89.4% versus 87.4% at 1 year, 80.1% versus 77.8% at 2 years, and 72.9% versus 69.8% at 3 years. The difference in survival estimates was significant (log-rank test P=0.01). In as-treated analysis of Medicare primary payer patients, 240 (15.1%) and 1653 (20.8%) deaths occurred in DHHD and matched in-center patients, respectively. Corresponding mortality rates were 112 and 137 deaths per 1000 patient-years, with mean follow-up of 1.4 and 1.5 years, respectively. Survival estimates are displayed in Figure  1B . Survival percentages for DHHD versus in-center patients were 89.4% versus 87.3% at 1 year, 80.0% versus 76.7% at 2 years, and 71.7% versus 67.6% at 3 years. The difference in survival estimates was likewise significant (P=0.01).
Relative hazards of death for DHHD versus matched incenter patients from unadjusted Cox regression are displayed in Table 2 . In intention-to-treat analysis of all-cause mortality, the mortality hazard ratio (HR) for DHHD versus in-center patients was 0.87 (95% confidence interval [CI], 0.78-0.97). Cause-specific mortality HRs were 0.92 (95% CI, 0.78-1.09) for cardiovascular disease (percentage of all deaths in in-center patients, 43.0%), 1.13 (95% CI, 0.84-1.53) for infection (11.1%), 0.63 (95% CI, 0.41-0.95) for cachexia/dialysis withdrawal (9.6%), 1.06 (95% CI, 0.81-1.37) for other specified cause (15.8%), and 0.59 (95% CI, 0.44-0.79) for unknown cause (20.5%). The all-cause mortality HR shifted from 0.88 to 0.95 in the first 2 years of follow-up, but the trend was not significant (P=0.97). Findings were insensitive to modelbased adjustment of matching factors, as the only imbalanced factor (dual eligibility) was unassociated with risk of death (HR, 0.98). In as-treated analysis, the mortality HR for DHHD versus in-center patients was 0.82 (95% CI, 0.72-0.94). Cause-specific mortality HRs were 0.83 (95% CI, 0.67-1.01) for cardiovascular disease (percentage of all deaths in in-center patients, 43.9%), 1.17 (95% CI, 0.83-1.66) for infection (11.1%), 0.70 (95% CI, 0.44-1.11) for cachexia/dialysis withdrawal (9.9%), 1.19 (95% CI, 0.88-1.61) for other specified cause (14.6%), and 0.41 (95% CI, 0.28-0.62) for unknown cause (20.6%). The all-cause mortality HR shifted from 0.77 to 0.89 in the first 2 years of follow-up, but the trend was not significant (P=0.78).
All-cause mortality HRs for DHHD versus matched incenter patients in intention-to-treat analysis are displayed across strata in Figure 2 . All HRs were ,1. Among the nine pairs of strata, the largest intra-pair differences in HRs were for body mass index (BMI) 3.1% initiated peritoneal dialysis. After DHHD cessation, the intention-to-treat mortality rate was 160 deaths per 1000 patient-years.
Sensitivity Analyses
As a sensitivity analysis, we considered robustness of the intention-to-treat all-cause mortality HR for DHHD versus matched in-center patients (0.87), with respect to adjustment for a hypothetical unmeasured binary factor U (e.g., "physical and mental capacity to self-dialyze"), stipulated to be independently associated with risk of death. The sensitivity analysis provides a theoretical answer to a practical question: "How imbalanced must an unmeasured risk factor for death be to account for the observed mortality reduction?" Findings are displayed in Table 3 . In all cases, we assumed that U was present in all DHHD patients. If the HR for presence versus absence of U were 0.9, then the HR for DHHD versus in-center hemodialysis would remain ,1, regardless of the prevalence of U in matched in-center patients. However, if the HR for presence versus absence of U were 0.8, 0.7, 0.6, or 0.5, then the HR for DHHD versus in-center hemodialysis would exceed 1 if prevalence of U in matched in-center patients were #40%, 65%, 77%, or 85%, respectively.
DISCUSSION
In this study, we compared mortality of DHHD patients who initiated renal replacement therapy with the NxStage System One from 2005 to 2007 with matched thriceweekly in-center hemodialysis patients. Matching factors included first date of follow-up, demographic characteristics, and measures of disease severity. Although DHHD patients were considerably younger with less comorbidity than the entire population of in-center patients, matching successfully balanced 16 of 17 measured factors, thereby yielding improved estimates of relative mortality between DHHD and in-center hemodialysis. We found that risk of death for DHHD patients was 13% and 18% lower in intention-to-treat and as-treated analyses, respectively, although relative risks varied considerably across causes of death. Relative risks did not vary significantly during follow-up or across patient strata; however, the sample size afforded limited power to detect heterogeneity of treatment effects.
Existing evidence of a beneficial effect of frequent hemodialysis on risk of death is weak. The Frequent Hemodialysis Network (FHN) trial recently found a large beneficial effect of six versus three in-center hemodialysis sessions per week on the composite endpoint of change in left-ventricular mass and death (HR, 0.61). 4 With only 14 deaths in the trial (five and nine in patients who were randomized to six and three sessions per week, respectively), the difference was primarily a function of greater left-ventricular mass regression in patients who dialyzed frequently. Left-ventricular mass is a strong predictor of cardiovascular risk in dialysis patients, but unlike in the hypertensive population, regression does not necessarily portend improved outcomes; harm associated with complete correction of anemia is a case in point. [13] [14] [15] [16] [17] Even if left-ventricular mass regression were to reduce the risk of major adverse cardiovascular events, the magnitude of mortality risk reduction would likely be ,39%. 18 In addition, nonrandomized studies of frequent hemodialysis may elicit skepticism, because selection of appropriate controls is not straightforward. Published estimates of mortality risk reductions with daily hemodialysis range from 36% to 66% in as-treated analysis (Table 4) . [7] [8] [9] [10] [11] All except one of these studies used the adjustment technique of indirect standardization to derive standardized mortality ratios, with the United States in-center population as the referent. Although this statistical approach is theoretically adequate, it is not well suited for high-dimensional adjustment. Lack of adjustment for confounding factors beyond age, race, sex, primary ESRD cause, and ESRD duration limits the value of findings from these studies; as a frame of reference, the intention-to-treat allcause mortality HR in this study would have been 0.73 if we had included only age, race, sex, and primary ESRD cause as matching factors. Just as peritoneal dialysis patients in the United States have less comorbidity than hemodialysis patients, DHHD patients in this study were markedly healthier than their counterparts in the entire in-center population, with less cardiovascular disease, fewer hospital days, and a greater likelihood of being wait-listed for transplant. 19 The lower risk of death associated with DHHD in this study was primarily due to reduced risks of death from cardiovascular disease and unknown causes, because these accounted for Figure 2 . Relative hazards of death for daily home hemodialysis patients in intention-to-treat analysis, by strata (referent: matched thrice-weekly in-center hemodialysis patients). HRs are displayed by dark circles and 95% CIs by solid lines. Cardiovascular disease was defined by any of atherosclerotic heart disease, cerebrovascular disease, congestive heart failure, peripheral vascular disease, or other cardiovascular disease. MPP, Medicare as primary payer. 4, 5 Less severe hypertension generally reduces risk of cardiovascular morbidity, but lack of BP targeting trials in dialysis patients limits conclusions about the importance of this effect. 20 Despite mixed findings in observational studies, the FHN trial definitively showed that frequent hemodialysis decreased predialysis serum phosphorus, of which higher levels are associated with increased coronary vessel and valvular calcification. 4, 21 In addition, frequent hemodialysis should reduce predialysis serum potassium, possibly reducing risk of cardiovascular mortality attributable to hyperkalemia. 22 The reduction in unspecified causes of death is likely multifactorial. Importantly, cause of death is unknown when the ESRD Death Notification form is not submitted; thus, the observed reduction may merely represent further risk reductions in death due to cardiovascular disease and cachexia/ dialysis withdrawal. Findings from previous studies are compatible with the hypothesis that daily hemodialysis improves Kidney Disease Quality of Life scores, which have been correlated with mortality risk. 23 In the FHN trial, the physical health composite score improved significantly with frequent hemodialysis. 4 In the ongoing Following Rehabilitation, Economics, and Everyday Dialysis Outcome Measurements study, daily hemodialysis patients had fewer depressive symptoms, better sleep quality, and shorter postdialysis recovery time. 24, 25 Depression severity has been identified as a predictor of dialysis withdrawal 26 ; risk of death from dialysis withdrawal was markedly lower in DHHD patients in this study. In addition, frequent hemodialysis typically reduces intensity of pharmacological treatment, with decreased use of antihypertensive agents and phosphate binders. 4, 27, 28 Given the pill burden on ESRD patients, fewer medications might be more efficacious, insofar as adherence may improve. 29 More frequent dialysis may confer some risk. In the FHN trial, relative hazards of time to first (HR, 1.71) and multiple (HR, 1.35) vascular access interventions were higher in patients who were randomized to six sessions per week. 4 We found increased risk of infectious mortality in DHHD. Although the association lacked statistical significance, it is likely an important safety signal. Home dialysis requires diligent antibacterial practices to prevent infection of dialysis equipment and the vascular access site. The latter is salient because arteriovenous fistulas have been identified as the predominant method of vascular access in frequent hemodialysis patients. 30 Daily cannulation of fistulas may increase risk of access infections, particularly in patients who use the buttonhole technique. 31 That DHHD patients dialyze at home raises the possibility that acute infections may not be identified by providers until they spread, resulting in septicemia or cardiac infection. Future studies should probe morbidity (e.g., resulting in hospitalization), as well as the roles of vascular access techniques in infectious mortality and depression in deaths after dialysis withdrawal.
Relative risks did not vary significantly during follow-up or across patient strata, but we observed some potentially important variation. Interval analysis indicated attenuation of the DHHD mortality advantage during the first 2 years of follow-up. This pattern may reflect growing fatigue with the daily dialysis regimen, as reported in a prospective study of five daily in-center hemodialysis patients. 32 However, estimates of relative survival in later intervals mostly rely on follow-up data from patients who initiated DHHD in 2005 and 2006. We found that survival was better for patients who initiated DHHD in 2007 than for their predecessors, suggesting serial improvement in patient training and technique execution. Interestingly, we also found that patients with diabetes and higher BMI (itself correlated with diabetes) benefited relatively more from DHHD. In an analysis of 22 daily hemodialysis patients with mean treatment duration of almost 5 years, hyperinsulinemia was rare, suggesting improved insulin sensitivity. 33 Because insulin resistance may lead to hypertension and dyslipidemia, one could speculate that patients with diabetes and/or obesity gain greater potential benefit from frequent dialysis.
This study has two major limitations. First, we used matching in lieu of randomization. We achieved balance in almost all matching factors, and sensitivity analysis showed that only a strong unmeasured confounder (e.g., with HR=0.8 and prevalence difference $60%) could alone undo the observed association of DHHD with mortality. However, this analysis does not eliminate the possibility that many weaker unmeasured confounders could collectively undo the association. Uncontrolled differences in disease severity (as measured by serum concentrations), educational attainment, social support, and socioeconomic status may underlie observed survival differences. 34 Second, approximately 1 in 4 DHHD patients switched to in-center hemodialysis during followup. The high rate of DHHD cessation limits the capability of intention-to-treat analysis to discern the clinical effects of DHHD treatment. However, as-treated analysis is not necessarily superior, because sicker patients may be more likely to cease DHHD, thereby biasing HR estimates. To limit bias, we followed patients for 2 months after DHHD cessation. This study also has four minor limitations. First, we used Medicare claims to identify measures of disease severity. Misclassification of comorbid conditions is likely. However, highly important matching factors, including age, hospital days, and epoetin alfa dose, were measured with minimal error. Second, because cause of death is unknown in 10%-20% of cases, estimates of cause-specific mortality HRs must be interpreted with caution. Third, we estimated the association of DHHD with mortality in a relatively young and healthy subset of the ESRD population. DHHD patients likely had some social support. The findings in this study may not apply to thriceweekly in-center patients without the physical and mental capacity and social support to effectively dialyze at home. Finally, we did not have data regarding dialysis adequacy, dose, or frequency during follow-up.
Frequent hemodialysis in general and DHHD in particular may confer benefits on ESRD patients. The FHN trial and this study together suggest that frequent hemodialysis improves cardiovascular health, resulting in a modest improvement in survival. Because of possible safety concerns regarding infection with DHHD, continued surveillance and improvements in patient education are warranted. As with peritoneal dialysis, patients and providers should carefully consider the benefits and harms of DHHD, as well as its feasibility, whereas policymakers should design incentives that maximize its use in clinically appropriate subgroups. Using personal identifiers and sex, we linked 2802 records (99.5%) to data in the USRDS database. We identified 2723 patients, including 2645 with 1 record, 77 with 2 records, and 1 with 3 records. Of patients with multiple records, 32 had replicate records, aside from name spelling differences; 9 had pairs of records indicating transfers between home dialysis programs with no interruption in DHHD; 18 had pairs indicating transfers between programs with possible interruptions of no longer than 1 month; and 19 had pairs indicating interruptions of longer than 1 month. For patients with possible interruptions of no longer than 1 month, we ignored gaps in treatment and merged the record pairs. For patients with interruptions of longer than 1 month, we retained only the first record. For specificity, we included patients with five or six prescribed dialysis sessions per week (n=2617). Finally, we required Medicare primary payer status during the 3 months preceding NxStage System One use initiation, or beginning of renal replacement therapy during the 6 months preceding use initiation (n=1873). These conditions allowed us to use data from the Medical Evidence Report (Centers for Medicare and Medicaid form CMS-2728) and Medicare claims as temporally proximal measures of baseline health status.
CONCISE METHODS
Protection of Human Participants
The source cohort of thrice-weekly in-center patients included all patients who were treated with in-center hemodialysis between January 1, 2005, and December 31, 2007 (n=637,109) .
Data Elements
For each DHHD patient, we identified age, race, sex, primary ESRD cause, ESRD duration, BMI, atherosclerotic heart disease, congestive heart failure, cerebrovascular disease, peripheral vascular disease, other cardiovascular disease, cancer, diabetes, concurrent Medicare and Medicaid enrollment (dual eligibility), cumulative epoetin alfa dose, cumulative hospital days, and kidney transplant waiting list registration. Age, ESRD duration, dual eligibility, and waiting list registration were defined at NxStage System One use initiation (index date). BMI was ascertained from the final outpatient dialysis claim during the 3 months preceding the index date, or in lieu of claims with BMI data, from the Medical Evidence Report. In patients with Medicare as primary payer, epoetin alfa dose and hospital days were measured from outpatient and inpatient claims, respectively, during the 3 months preceding the index date; in patients without Medicare as primary payer, dose and days were unknown. Comorbid conditions were defined from the Medical Evidence Report and claims during the 6 months preceding the index date; in claims, we required at least one inpatient or two outpatient claims with relevant diagnosis codes to define disease. 35 Dual eligibility is a coarse measure of socioeconomic status, as Medicaid eligibility requires very low annual income and assets.
For each in-center patient, we iteratively identified all aforementioned factors with respect to each day of hemodialysis between January 1, 2005, and December 31, 2007. Also on each day, we determined Medicare primary payer status during the 3 preceding months, and if Medicare was not the primary payer, whether renal replacement therapy began during the 6 preceding months.
Matching Algorithm
For each DHHD patient, we selected 5 thrice-weekly in-center patients with matching characteristics. To do so, we initially retained only incenter patients who underwent hemodialysis on the index date of the DHHD patient. Next, if the DHHD patient had Medicare as primary payer, we retained the subset of in-center patients with Medicare as primary payer; if not, we retained the subset of non-Medicare primary payer patients who began renal replacement therapy during the 6 preceding months. Subsequently, we iteratively winnowed the set of in-center candidate matches according to an ordering of aforementioned factors and factor-specific definitions of sufficient similarity ( Table 5 ). The ordering was determined from survival analysis of all in-center patients alive on January 1, 2007, with follow-up until the earlier of death or December 31, 2008. We fit a Cox proportional hazards regression with all factors, with stratification by Medicare primary payer status. We also fit each model with one factor removed, and calculated the deviance of the model from the model with all factors. The ordering represents a descending list of deviance estimates.
If any iterative winnowing of candidate matches resulted in ,5 candidates, the algorithm was reversed 1 factor, and 5 candidates were randomly selected. If execution of the entire algorithm resulted in .5 candidates, 5 were randomly selected.
Statistical Analyses
We calculated tabular summaries of measured factors in DHHD patients, all in-center patients alive on January 1, 2007, and matched in-center patients. We assessed match quality with standardized differences; differences ,10% indicate similarity. 36 We calculated survival estimates with the Kaplan-Meier method. We used both intention-totreat and as-treated analyses. In the former, we followed patients from the index date of the DHHD patient in the matched cluster to the earlier of death or December 31, 2008 . In the latter, we followed patients from the index date to the earlier of death, 2 months after change of dialytic modality (from DHHD to in-center hemodialysis or peritoneal dialysis, or from in-center hemodialysis to peritoneal dialysis), kidney transplant, cessation of Medicare as primary payer, or December 31, 2008 ; the 2-month extension after change of dialytic modality effectively assigned deaths and survival time to the first modality. As-treated analysis was restricted to Medicare primary payer patients to ensure ascertainment of modality changes. We compared survival with Cox regression, with and without model-based adjustment for factors already included in the matching algorithm. We compared all-cause and cause-specific survival with cause ascertained from the Death Notification form (Centers for Medicare and Medicaid form CMS-2746). We also assessed whether effects of DHHD versus in-center hemodialysis on survival varied by follow-up interval. In intention-to-treat analysis, we compared survival within nine strata defined by matching factors. In Medicare primary payer patients, we compared times to change in dialytic modality, kidney transplant, and cessation of Medicare primary payer status with Cox regression, and in the subset of DHHD patients, we identified predictors of time to change in dialytic modality with multivariate Cox regression. Finally, we assessed the sensitivity of the intention-to-treat all-cause mortality HR to adjustment for an unmeasured factor, as described by Lin et al. 37 
